Filings & corporate actions
73 results filed
CSVNext results · Q2 FY27
Expected 21 Oct 2026 – 11 Nov 2026
Estimate: filed 21–42 days after quarter end, last 5 times
Dividend
₹4.00 per share · last 4 Sept 2026
2026
- 4 SeptdividendDividend · ₹4.00 per share-0.4%
- 29 JulresultsResults · Q1 FY27 · standalone+2.4%NSE
- 13 JulshareholdingShareholding · 30 Jun 2026-1.2%NSE
- 9 JunshareholdingShareholding · 2 Jun 2026+1.6%NSE
- 4 MaybuybackBuy Back+1.2%
- 27 AprresultsResults · Q4 FY26 · standalone+0.9%NSE
- 21 AprshareholdingShareholding · 31 Mar 2026+6.0%NSE
- 21 JanresultsResults · Q3 FY26 · standalone+0.5%NSE
- 15 JanshareholdingShareholding · 31 Dec 2025-1.1%NSE
Reaction to results · all yearsrose on day 0 in 30 of 74 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 29 Jul 2026 | +2.4% | +3.3% | +2.8% | 145.1× |
| Q4 FY26 | 27 Apr 2026 | +0.9% | +3.1% | +2.6% | 2.2× |
| Q3 FY26 | 21 Jan 2026 | +0.5% | +2.7% | +5.2% | 4.2× |
| Q2 FY26 | 3 Nov 2025 | -4.4% | -5.5% | -4.7% | 2.2× |
| Q1 FY26 | 26 Jul 2025 | +11.2% | +3.6% | -11.2% | 25.7× |
| Q4 FY25 | 6 May 2025 | -8.6% | -9.4% | -6.4% | 1.1× |
| Q3 FY25 | 23 Jan 2025 | -4.1% | -2.1% | -14.3% | 3.4× |
| Q2 FY25 | 24 Oct 2024 | +0.9% | +14.7% | +41.7% | 3.1× |
| Q1 FY25 | 8 Aug 2024 | -0.3% | +2.4% | +15.4% | 1.2× |
| Q4 FY24 | 21 May 2024 | -2.7% | -6.4% | -6.0% | 1.0× |
| Q3 FY24 | 2 Feb 2024 | -16.6% | -16.6% | -15.7% | 12.9× |
| Q1 FY24 | 3 Aug 2023 | -4.1% | -1.7% | -10.9% | 0.3× |
| Q4 FY23 | 24 May 2023 | -0.7% | +3.3% | +6.6% | 0.7× |
| Q3 FY23 | 10 Feb 2023 | +0.9% | +1.0% | -9.5% | 1.6× |
| Q2 FY23 | 10 Nov 2022 | +0.5% | -7.5% | +6.7% | 1.2× |
| Q1 FY23 | 10 Aug 2022 | +7.8% | +9.0% | +11.2% | 4.3× |
| Q4 FY22 | 31 May 2022 | -0.5% | +0.7% | +3.9% | 0.7× |
| Q3 FY22 | 13 Feb 2022 | -2.0% | +22.8% | +46.7% | 1.9× |
| Q2 FY22 | 21 Oct 2021 | -0.8% | +9.3% | -6.6% | 1.3× |
| Q1 FY22 | 14 Aug 2021 | -3.1% | -16.5% | -10.2% | 0.8× |
| Q4 FY21 | 2 Jul 2021 | -4.6% | +13.3% | +28.0% | 0.7× |
| Q3 FY21 | 12 Feb 2021 | +2.0% | +3.7% | +7.4% | 1.5× |
| Q2 FY21 | 11 Nov 2020 | +0.3% | +57.5% | +78.3% | 0.5× |
| Q4 FY20 | 30 Jul 2020 | -4.3% | -1.8% | +17.1% | 1.8× |
| Q1 FY21 | 30 Jul 2020 | -4.3% | -1.8% | +17.1% | 1.8× |
| Q3 FY20 | 14 Feb 2020 | 0.0% | +3.7% | -26.1% | 0.6× |
| Q2 FY20 | 15 Nov 2019 | +2.4% | -1.0% | -5.3% | 0.4× |
| Q1 FY20 | 14 Aug 2019 | -3.6% | -13.8% | +5.6% | 0.1× |
| Q4 FY19 | 29 May 2019 | +6.9% | +6.9% | -1.8% | 2.7× |
| Q3 FY19 | 27 Feb 2019 | -1.8% | +2.7% | -4.5% | 1.7× |
| Q2 FY19 | 27 Nov 2018 | -1.3% | -3.9% | +6.0% | 0.7× |
| Q1 FY19 | 28 Aug 2018 | +1.3% | +14.7% | -7.8% | 1.0× |
| Q4 FY18 | 28 Jun 2018 | 0.0% | -2.0% | +5.5% | 0.3× |
| Q3 FY18 | 28 Feb 2018 | -2.0% | -11.8% | -13.0% | 0.6× |
| Q2 FY18 | 13 Dec 2017 | -1.8% | +8.0% | +19.2% | 0.9× |
| Q1 FY18 | 24 Aug 2017 | 0.0% | -1.2% | +2.8% | 0.5× |
| Q4 FY17 | 15 Jun 2017 | -2.9% | -2.3% | -2.3% | 0.4× |
| Q3 FY17 | 21 Feb 2017 | -0.9% | -2.5% | -5.3% | 0.3× |
| Q2 FY17 | 12 Nov 2016 | -8.9% | -25.3% | -5.9% | 1.6× |
| Q1 FY17 | 26 Aug 2016 | -0.7% | -1.4% | +10.0% | 0.7× |
| Q4 FY16 | 30 May 2016 | +1.9% | +19.5% | +23.7% | 2.2× |
| Q3 FY16 | 14 Feb 2016 | +4.4% | +2.6% | +11.0% | 0.5× |
| Q2 FY16 | 13 Nov 2015 | -0.8% | +12.9% | +34.8% | 0.6× |
| Q1 FY16 | 16 Aug 2015 | -1.2% | -4.5% | -6.6% | 0.3× |
| Q4 FY15 | 5 Jun 2015 | +2.7% | -7.6% | +8.7% | 1.7× |
| Q3 FY15 | 19 Feb 2015 | +6.8% | -0.5% | -2.3% | 1.2× |
| Q2 FY15 | 21 Nov 2014 | -4.3% | +8.2% | +3.9% | 1.3× |
| Q4 FY14 | 7 Jun 2014 | +1.6% | -4.7% | +10.2% | 0.8× |
| Q3 FY14 | 15 Feb 2014 | -1.2% | -4.8% | -7.1% | 0.2× |
| Q2 FY14 | 21 Nov 2013 | 0.0% | -4.2% | +2.8% | 3.4× |
| Q1 FY14 | 21 Aug 2013 | -10.0% | -10.0% | 0.0% | 0.2× |
| Q4 FY13 | 19 Jun 2013 | 0.0% | -2.7% | +8.1% | 7.0× |
| Q3 FY13 | 19 Feb 2013 | -2.1% | -14.4% | -9.3% | 0.2× |
| Q1 FY13 | 21 Aug 2012 | +2.1% | +8.5% | +21.3% | 1.8× |
| Q4 FY12 | 7 Jun 2012 | 0.0% | +2.0% | +13.3% | 1.0× |
| Q3 FY12 | 13 Feb 2012 | +4.3% | +6.9% | 0.0% | 4.8× |
| Q2 FY12 | 17 Nov 2011 | +1.1% | -2.2% | -6.5% | 1.1× |
| Q1 FY12 | 19 Aug 2011 | +2.0% | +4.1% | +16.3% | 0.7× |
| Q4 FY11 | 13 May 2011 | -11.6% | -13.2% | -5.4% | 8.4× |
| Q3 FY11 | 12 Feb 2011 | -4.6% | -1.5% | -7.7% | 3.1× |
| Q2 FY11 | 13 Nov 2010 | +0.9% | -12.2% | -14.6% | 0.9× |
| Q1 FY11 | 14 Aug 2010 | +8.6% | +16.6% | +18.9% | 11.8× |
| Q4 FY10 | 13 May 2010 | -2.2% | -13.0% | -12.5% | 1.0× |
| Q3 FY10 | 30 Jan 2010 | +4.8% | 0.0% | -5.4% | 0.2× |
| Q2 FY10 | 29 Oct 2009 | 0.0% | -1.5% | -1.5% | 0.4× |
| Q1 FY10 | 29 Jul 2009 | -0.9% | +1.8% | +18.9% | 0.7× |
| Q4 FY09 | 30 Jun 2009 | -2.9% | -13.5% | +6.7% | 0.1× |
| Q3 FY09 | 28 Jan 2009 | +1.7% | +5.0% | +3.3% | 0.5× |
| Q2 FY09 | 1 Nov 2008 | +6.7% | +16.7% | -3.3% | 0.9× |
| Q1 FY09 | 29 Jul 2008 | -2.7% | +2.7% | -6.2% | 0.3× |
| Q4 FY08 | 2 May 2008 | +1.5% | -5.9% | -12.5% | 1.3× |
| Q3 FY08 | 31 Jan 2008 | -3.3% | -2.0% | -6.0% | 0.4× |
| Q1 FY08 | 28 Jul 2007 | +3.0% | -1.5% | -0.7% | 0.7× |
| Q4 FY07 | 30 Apr 2007 | +2.9% | +4.3% | +4.3% | 0.7× |
| Average | -0.5% | +0.6% | +3.7% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+8.8%
Profit YoY+22.2%
Interest cost YoY—
Revenue QoQ+28.1%
Profit QoQ+50.5%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
CSVOpen228.90
Day range227.01 – 235.99
52-week range155.00 – 264.50
From 52w high-11.7%
RSI (14)49.8
ATR (14)9.61
Volume58.6K
Avg volume (20D)5.81L
Rel volume0.10×
Volatility (1Y)32.1%
Turnover₹1.4Cr
SMA 50 / 200234.11 / 205.70
Delivery percentage
Latest · 6 Oct 202655.4%
20-day avg46.8%
1-year avg51.3%
Percentile (own history)58th
Range4.9–100.0%
Sessions1,731
Over the last 20 sessions JAGSNPHARM settled 46.8% of its traded quantity, which is above average for an NSE equity. Its one-year average is 51.3%, so recent sessions are running 4.5 points lower than usual. The latest session ranks higher than 58% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +1.81% | -3.07% | -3.86% | -2.13% | +25.46% | +8.69% |
Valuation
CSVMarket cap₹1,541 Cr
P/E (TTM)33.9
EPS (TTM)6.89
Shares outstanding6.58Cr
Listed1 Mar 2000
Ownership
CSVPromoter—
Promoter Δ QoQ—
Public—
FII—
DII—
Pledged—
Quarterly results · standalone
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 74.5 | 72.9 | 64.2 | 82.2 |
| YoY chg | — | — | +9.6% | +8.8% |
| Net profit (₹ Cr) | 12.6 | 11.0 | 8.8 | 13.2 |
| YoY chg | — | — | +33.1% | +22.2% |
| Net margin | 16.9% | 15.0% | 13.6% | 16.0% |
| EPS | 1.87 | 1.65 | 1.21 | 1.98 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 69.05% · public 30.95%2021-092026-06
- Promoter
- Public and others
- Promoter
- 69.05%
- Public
- 30.95%
- Promoter change
- -0.31 pp
- Filed
- 13 Jul 2026
- FII
- 2.30%
- DII
- 0.62%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSVStandalone
₹ crore, as filed
| Q1 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 60.2 | 47.2 | 43.5 | 61.4 | 74.7 | 74.0 | 58.6 | 75.6 | 74.5 | 72.9 | 64.2 | 82.2 | |
| Other income | 2.0 | 2.5 | 2.5 | 1.4 | 1.7 | 2.3 | 2.8 | 2.8 | 3.0 | 3.0 | 3.2 | 2.8 | |
| Total income | 62.2 | 49.8 | 46.0 | 62.9 | 76.3 | 76.3 | 61.3 | 78.4 | 77.5 | 75.9 | 67.4 | 85.1 | |
| Total expenses | 52.1 | 44.5 | 41.4 | 52.5 | 61.0 | 60.9 | 52.4 | 64.0 | 60.7 | 59.3 | 55.6 | 67.4 | |
| └ Finance costs | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
| └ Depreciation | 0.4 | 0.4 | 0.4 | 1.1 | 2.3 | 2.4 | 2.3 | 2.4 | 2.4 | 2.4 | 2.3 | 2.1 | |
| Profit before tax | 10.1 | 5.3 | 4.5 | 7.1 | 15.4 | 38.7 | 8.7 | 14.4 | 16.8 | 14.5 | 11.8 | 17.7 | |
| Tax expense | 2.6 | 1.3 | 1.0 | 1.8 | 3.9 | 6.7 | 2.1 | 3.6 | 4.2 | 3.6 | 3.0 | 4.5 | |
| Net profit | 7.5 | 4.0 | 3.5 | 5.3 | 11.5 | 32.0 | 6.6 | 10.8 | 12.6 | 11.0 | 8.8 | 13.2 | |
| EPS | 1.14 | 0.59 | 0.52 | 0.78 | 1.72 | 1.90 | 0.98 | 1.60 | 1.88 | 1.67 | 1.25 | 2.00 | |
| Net margin | 12.43% | 8.39% | 8.16% | 8.67% | 15.34% | 43.22% | 11.24% | 14.28% | 16.89% | 15.01% | 13.65% | 16.04% | |
| PBT margin | 16.78% | 11.18% | 10.43% | 11.57% | 20.58% | 52.24% | 14.87% | 19.09% | 22.57% | 19.91% | 18.31% | 21.50% | |
| Tax rate | 25.88% | 24.93% | 21.76% | 25.05% | 25.44% | 17.28% | 24.40% | 25.20% | 25.20% | 24.59% | 25.47% | 25.40% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 29 Jul 2026.
JAGSNPHARM at a glance
- JAGSNPHARM closed at ₹233.63 on 6 Oct 2026, +1.81% on the day, +8.7% over one year, 11.7% below its 52-week high of ₹264.5.
- Delivery was 55.4% of traded quantity on 6 Oct 2026, the 58th percentile of its own 1,731 sessions with a reading (20-session average 46.8%, 1-year average 51.3%).
- Market capitalisation is ₹1,541 crore at a trailing P/E of 33.9 (trailing EPS ₹6.89).
- Q1 FY27 results (standalone, filed 29 Jul 2026): revenue ₹82 crore (+8.8% year on year), net profit ₹13 crore (+22.2%); the price moved +2.4% on the first session after.
- Promoters held 69.05% at 30 Jun 2026, down 0.31 percentage points on the previous filing.
- Q2 FY27 results are expected between 21 Oct 2026 and 11 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE048B01035
SeriesEQ
Listed1 Mar 2000
History from13 Sept 1996
Sessions7,117
Turnover rank#912
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE